These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Simplifying suppression: switching therapies to improve HIV disease management. Moyle GJ AIDS Read; 2004 Jul; 14(7):380-4. PubMed ID: 15282867 [No Abstract] [Full Text] [Related]
3. [Metabolic complications associated with use of protease inhibitors]. Mosnier-Pudar H Ann Med Interne (Paris); 2000 Jun; 151(4):278-82. PubMed ID: 10922955 [TBL] [Abstract][Full Text] [Related]
5. [HIV-lipodystrophy syndrome]. Mauss S; Schmutz G Med Klin (Munich); 2001 Jul; 96(7):391-401. PubMed ID: 11494914 [TBL] [Abstract][Full Text] [Related]
6. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. Leitz G; Robinson P AIDS; 2000 Mar; 14(4):468-9. PubMed ID: 10770555 [No Abstract] [Full Text] [Related]
7. Damage to the power plant. TreatmentUpdate; 2002 Mar; 14(3):1-2. PubMed ID: 12033185 [No Abstract] [Full Text] [Related]
8. Substitution for protease inhibitors in HIV therapy. Mikhail E N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602 [No Abstract] [Full Text] [Related]
9. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Brinkman K; Smeitink JA; Romijn JA; Reiss P Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516 [TBL] [Abstract][Full Text] [Related]
10. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798 [TBL] [Abstract][Full Text] [Related]
11. Report from the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Confrancesco J Hopkins HIV Rep; 2003 Jan; 15(1):4-5. PubMed ID: 12542003 [No Abstract] [Full Text] [Related]
12. Anti-HIV agents. Leading to lipodystrophy. TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312 [No Abstract] [Full Text] [Related]
13. [Metabolic disturbances associated with HAART]. Olczak A Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495 [TBL] [Abstract][Full Text] [Related]
14. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA; AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957 [TBL] [Abstract][Full Text] [Related]
16. Meeting report from the XV International AIDS Conference. Metabolic complications. Currier J AIDS Clin Care; 2004 Sep; 16(9):73-4. PubMed ID: 15540318 [No Abstract] [Full Text] [Related]
17. [Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data]. Urso R; Croce GF; Tubili C; De Marco M; La Scala P; Luglio D; Narciso P Recenti Prog Med; 2000 Feb; 91(2):78-85. PubMed ID: 10748653 [TBL] [Abstract][Full Text] [Related]
18. Buffalo hump: what the experts suggest. Piliero PJ; McComsey GA AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294 [No Abstract] [Full Text] [Related]
19. Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report. Alcaide ML; Kolber M; Jayaweera D Int J STD AIDS; 2002 Nov; 13(11):795-6. PubMed ID: 12437905 [No Abstract] [Full Text] [Related]